Polish pharmaceutical company Biomed Lublin have successfully completed the production of a drug for Covid-19 - announced the CEO of Biomed Lublin.
Now the firm plans to begin non-commercial clinical trials, and – if all goes well – Poland could be the first country in the world to have an effective drug capable of neutralizing the SARS-CoV-2 virus at some stage over the next few months.
Biomed Lublin says that the drug is made by fractionating the plasma of healthy people – those who recovered from or those who had Covid-19 asymptomatically – and contains anti-SARS-CoV-2 immunoglobulins.
Emerging Europe quotes Marcin Piróg of Biomed Lublin as saying: “We have unequivocally proven that it is possible to produce a drug containing a concentrated dose of such antibodies and it can effectively use human plasma, which can be converted into a drug with a treatment efficiency greater than plasma alone.”
More than 3,000 capsules of anti-SARS-CoV-2 immunoglobulin have been produced, which after the completion of the required quality tests, including product stability, will be submitted to clinical trials. The release of the drug for non-commercial clinical trials is planned in the fourth quarter of 2020.
